Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Intervention to decrease glyburide use in elderly patients with renal insufficiency.

Aspinall SL, Zhao X, Good CB, Stone RA, Boresi J, Cox S, Bartholomew C, Jansen D, Guterman S, Patino M, Rivera-Miranda G, Burlingame M, Frazer J, Sellers J, Stanard Steele V, Witt L, Cunningham FE.

Am J Geriatr Pharmacother. 2011 Feb;9(1):58-68. doi: 10.1016/j.amjopharm.2011.02.001. Review.

PMID:
21459309
2.

Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide.

Skoff RA, Waterbury NV, Shaw RF, Egge JA, Cantrell M.

J Manag Care Pharm. 2011 Nov;17(9):664-71.

3.

Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.

Herz M, Sun B, Milicevic Z, Erickson P, Fövènyi J, Grzywa M, Pelikanova T.

Clin Ther. 2002 Jan;24(1):73-86.

PMID:
11833837
6.

Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.

Schwarz SL, Gerich JE, Marcellari A, Jean-Louis L, Purkayastha D, Baron MA.

Diabetes Obes Metab. 2008 Aug;10(8):652-60. Epub 2007 Oct 15.

PMID:
17941876
8.

Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study.

Weir MA, Gomes T, Mamdani M, Juurlink DN, Hackam DG, Mahon JL, Jain AK, Garg AX.

Nephrol Dial Transplant. 2011 Jun;26(6):1888-94. doi: 10.1093/ndt/gfq649. Epub 2010 Oct 25.

PMID:
20974644
9.

Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis.

Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP.

Diabetes Care. 2003 Jul;26(7):2075-80.

PMID:
12832316
10.

Effects of oral bisphosphonate therapy on serum calcium in elderly veterans with poor kidney function.

Vouri SM, Alvarez CA, Blaszczyk AT.

Am J Geriatr Pharmacother. 2012 Jun;10(3):178-84. doi: 10.1016/j.amjopharm.2012.04.001. Epub 2012 Apr 27.

PMID:
22542895
11.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
12.

Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.

Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, Gylvin T, Kawamori R.

Clin Ther. 2009 Aug;31(8):1641-51. doi: 10.1016/j.clinthera.2009.08.011.

PMID:
19808125
13.

Safety of glyburide for gestational diabetes: a meta-analysis of pregnancy outcomes.

Moretti ME, Rezvani M, Koren G.

Ann Pharmacother. 2008 Apr;42(4):483-90. doi: 10.1345/aph.1K577. Epub 2008 Mar 18.

PMID:
18349305
15.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
16.

FDA warning and removal of rosiglitazone from VA national formulary.

Aspinall SE, Zhao X, Good CB, Stone RA, Smith KJ, Cunningham FE.

Am J Manag Care. 2013 Sep;19(9):748-58.

18.

A retrospective analysis of the fasting plasma glucose and glycosylated hemoglobin and pharmacotherapy change patterns among type 2 diabetes mellitus patients.

Davidson J, Koro C, Arondekar B, Lee BH, Fedder D.

Clin Ther. 2008 Feb;30(2):287-93. doi: 10.1016/j.clinthera.2008.02.007.

PMID:
18343267
19.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
20.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987

Supplemental Content

Support Center